More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

The US is the single largest pharmaceutical market in the world, but it lags behind other countries in API production for drugs marketed in the US. How are the supply lines for APIs evolving for US-marketed drugs? API supply lines for US...

Biosimilars represent a small part of the global pharmaceutical market with Europe leading in biosimilar approvals comparative to the US. What are the challenges and opportunities for biosimilar uptake and what have been developments thus far in...

Earlier this month, FDA released results from its ongoing investigations of nitrosamine impurities in certain APIs, most recently ranitidine, and earlier “sartan”-containing APIs. What did the FDA find, and does it impact regulatory testing...

Parenteral drugs are an important part of the pharmaceutical market due to the increase in biologics and complex active pharmaceutical ingredients (APIs) in development. DCAT Value Chain Insights examines key product, manufacturing, and...

What are the key issues facing procurement and supply-chain leaders? From digital transformations to talent development to risk mitigation, DCAT Value Chain Insights provides perspective from thought leaders. Providing perspective is Robert...

With a $3-billion strategic alliance with Sumitomo Dainippon Pharma in the offing, Vivek Ramaswamy, CEO and founder of Roivant Sciences, is looking to take its “hub and spoke” business model for drug development to the next level. Inside Roivant...

The US Congressional Budget Office and the staff of the Joint Committee on Taxation have provided an analysis of the proposed drug pricing plan highlighted last month by US House of Representatives Speaker Nancy Pelosi (D-Calif.). What do they see...

Of the 12,300 medicines used in the UK, around 7,000 come from or via the European Union (EU), so what happens if the UK is not able to negotiate a deal as it faces an October 31 deadline to withdraw from the EU? How are the UK and the...

What’s behind continuing investment in manufacturing capabilities for high-potency APIs (HPAPIs)? The potential in innovator drugs is a driving factor, but the supply opportunities for generic drugs with HPAPIs also comes into play. High-potency...